LSD1/TLK1-IN-1

Overview

LSD1/TLK1-IN-1 is an orally active LSD1 , TLK1 , TLK2 , TTK inhibitor with an LSD1 IC 50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1> Nek1 >ATR> Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2 , MAO-A , or MAO-B . LSD1/TLK1-IN-1 induces apoptosis , bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PD-1/PD-L1 | Products > Signaling Pathways > Histone Demethylase | Products > Signaling Pathways > TLK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-149213
• CAS No.: 4734-59-2
• Molecular Formula: C18H20N2OS
• Molecular Weight: 312.43
• Purity: 99.20%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (8.00 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source